Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 853 to 856 of 856 entries
Sorted by: Best Match Show Resources per page
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.

Journal for immunotherapy of cancer

Brown LC, Desai K, Wei W, Kinsey EN, Kao C, George DJ, Rini BI, Ornstein MC, Zhang T.
PMID: 34518292
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-003281.

The combination of ipilimumab plus nivolumab (I+N) has greatly improved outcomes in patients with intermediate or poor-risk untreated metastatic renal cell carcinoma (mRCC). However, little is known about the outcomes of patients with brain metastasis (BrM) treated with I+N....

Cite
Brown LC, Desai K, Wei W, et al. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. J Immunother Cancer. 2021;9(9)doi: 10.1136/jitc-2021-003281.
Brown, L. C., Desai, K., Wei, W., Kinsey, E. N., Kao, C., George, D. J., Rini, B. I., Ornstein, M. C., & Zhang, T. (2021). Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for immunotherapy of cancer, 9(9), . https://doi.org/10.1136/jitc-2021-003281
Brown, Landon C, et al. "Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab." Journal for immunotherapy of cancer vol. 9,9 (2021). doi: https://doi.org/10.1136/jitc-2021-003281
Brown LC, Desai K, Wei W, Kinsey EN, Kao C, George DJ, Rini BI, Ornstein MC, Zhang T. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-003281. PMID: 34518292; PMCID: PMC8438842.
Copy Download .nbib Format: NLM
Recovery of Male Reproductive Function After Ceasing Prolonged Testosterone Undecanoate Injections.

European journal of endocrinology

Handelsman DJ, Desai R, Conway AJ, Shankara-Narayana N, Stuckey BG, Inder WJ, Grossmann M, Yeap BB, Jesudason D, Ly LP, Bracken K, Wittert GA.
PMID: 35000898
Eur J Endocrinol. 2022 Jan 01; doi: 10.1530/EJE-21-0608. Epub 2022 Jan 01.

CONTEXT: The time course of male reproductive hormone recovery after stopping injectable testosterone undecanoate (TU) treatment is not known.OBJECTIVE: To investigate rate, extent, and determinants of reproductive hormone recovery over 12 months after stopping TU injections.METHODS: Men (n=303) with...

Cite
Handelsman DJ, Desai R, Conway AJ, et al. Recovery of Male Reproductive Function After Ceasing Prolonged Testosterone Undecanoate Injections. Eur J Endocrinol. 2022;doi: 10.1530/EJE-21-0608.
Handelsman, D. J., Desai, R., Conway, A. J., Shankara-Narayana, N., Stuckey, B. G., Inder, W. J., Grossmann, M., Yeap, B. B., Jesudason, D., Ly, L. P., Bracken, K., & Wittert, G. A. (2022). Recovery of Male Reproductive Function After Ceasing Prolonged Testosterone Undecanoate Injections. European journal of endocrinology, . https://doi.org/10.1530/EJE-21-0608
Handelsman, David J, et al. "Recovery of Male Reproductive Function After Ceasing Prolonged Testosterone Undecanoate Injections." European journal of endocrinology vol. (2022). doi: https://doi.org/10.1530/EJE-21-0608
Handelsman DJ, Desai R, Conway AJ, Shankara-Narayana N, Stuckey BG, Inder WJ, Grossmann M, Yeap BB, Jesudason D, Ly LP, Bracken K, Wittert GA. Recovery of Male Reproductive Function After Ceasing Prolonged Testosterone Undecanoate Injections. Eur J Endocrinol. 2022 Jan 01; doi: 10.1530/EJE-21-0608. Epub 2022 Jan 01. PMID: 35000898.
Copy Download .nbib Format: NLM
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.

Circulation

Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV.
PMID: 33040613
Circulation. 2021 Jan 26;143(4):298-309. doi: 10.1161/CIRCULATIONAHA.120.050391. Epub 2020 Oct 12.

BACKGROUND: Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to...

Cite
Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2020;143(4):298-309doi: 10.1161/CIRCULATIONAHA.120.050391.
Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., Kitakaze, M., Merkley, B., O'Meara, E., Shou, M., Tereshchenko, S., Verma, S., Vinh, P. N., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Bengtsson, O., Langkilde, A. M., Sjöstrand, M., & McMurray, J. J. V. (2021). Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation, 143(4), 298-309. https://doi.org/10.1161/CIRCULATIONAHA.120.050391
Jhund, Pardeep S, et al. "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF." Circulation vol. 143,4 (2021): 298-309. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.050391
Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2021 Jan 26;143(4):298-309. doi: 10.1161/CIRCULATIONAHA.120.050391. Epub 2020 Oct 12. PMID: 33040613; PMCID: PMC7834909.
Copy Download .nbib Format: NLM
Reduced left atrial strain can predict stroke in atrial fibrillation - A meta-analysis.

International journal of cardiology. Heart & vasculature

Sachdeva S, Desai R, Andi K, Vyas A, Deliwala S, Sachdeva R, Kumar G.
PMID: 34485678
Int J Cardiol Heart Vasc. 2021 Aug 24;36:100859. doi: 10.1016/j.ijcha.2021.100859. eCollection 2021 Oct.

No abstract available.

Cite
Sachdeva S, Desai R, Andi K, et al. Reduced left atrial strain can predict stroke in atrial fibrillation - A meta-analysis. Int J Cardiol Heart Vasc. 2021;36:100859doi: 10.1016/j.ijcha.2021.100859.
Sachdeva, S., Desai, R., Andi, K., Vyas, A., Deliwala, S., Sachdeva, R., & Kumar, G. (2021). Reduced left atrial strain can predict stroke in atrial fibrillation - A meta-analysis. International journal of cardiology. Heart & vasculature, 36100859. https://doi.org/10.1016/j.ijcha.2021.100859
Sachdeva, Sonali, et al. "Reduced left atrial strain can predict stroke in atrial fibrillation - A meta-analysis." International journal of cardiology. Heart & vasculature vol. 36 (2021): 100859. doi: https://doi.org/10.1016/j.ijcha.2021.100859
Sachdeva S, Desai R, Andi K, Vyas A, Deliwala S, Sachdeva R, Kumar G. Reduced left atrial strain can predict stroke in atrial fibrillation - A meta-analysis. Int J Cardiol Heart Vasc. 2021 Aug 24;36:100859. doi: 10.1016/j.ijcha.2021.100859. eCollection 2021 Oct. PMID: 34485678; PMCID: PMC8391018.
Copy Download .nbib Format: NLM
Showing 853 to 856 of 856 entries